Cited by 1,930Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBlood transfusion and management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Open access

Besarab, Anatole, Bolton, W. Kline, Browne, Jeffrey K., Egrie, Joan C., Nissenson, Allen R., Okamoto, Douglas M., Schwab, Steve J., Goodkin, David A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199808273390903

Open this paper in CoChat — free account Open PDF

Abstract

BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199808273390903

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
(1990) · BMJ · doi:10.1136/bmj.300.6724.573 · Cited by 427
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401

Show all 28 references

Research works printed but not linked: 8

Pascual J, 1991, Clin Nephrol, 35, 280
Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
Collins A, 1994, J Am Soc Nephrol, 5, 439
Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
Barany P, 1996, J Am Soc Nephrol, 7, 1472
Benz RL, 1996, J Am Soc Nephrol, 7, 1473
Hoen B, 1995, Nephrol Dial Transplant, 10, 377
Collins A, 1997, J Am Soc Nephrol, 8, 190A

Sorted by citations

Items 101–200 of 1,000

Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2008.10.002 · Cited by 221
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)
Locatelli, F., Covic, A. C., Eckardt, K., Więcek, A., Vanholder, R. C., & on behalf of the ERA-EDTA ERBP Advisory Board (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn653 · Cited by 220
Survival in Daily Home Hemodialysis and Matched Thrice-Weekly In-Center Hemodialysis Patients
Weinhandl, E. D., Liu, J., Gilbertson, D. T., Arneson, T. J., & Collins, A. J. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011080761 · Cited by 220
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization
Westenbrink, B. D., Lipšic, E., van der Meer, P., van der Harst, P., Oeseburg, H., Sarvaas, G. J. D. M., Koster, J., Voors, A. A., van Veldhuisen, D. J., van Gilst, W. H., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm177 · Cited by 220
Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction
Najjar, S. S. (2011) · JAMA · doi:10.1001/jama.2011.592 · Cited by 219
The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients
Ofsthun, N. J., LaBrecque, J. F., Lacson, E., Keen, M. L., & Lazarus, J. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00937.x · Cited by 218
AHA Scientific Statement: AHA Dietary Guidelines
Krauss, R. M., Eckel, R. H., Howard, B. V., Appel, L. J., Daniels, S. R., Deckelbaum, R. J., Erdman, J. W., Kris‐Etherton, P. M., Goldberg, I. J., Kotchen, T. A., et al. (2001) · Journal of Nutrition · doi:10.1093/jn/131.1.132 · Cited by 215
Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury
Zager, R. A., Johnson, A. C. M., Hanson, S. Y., & Wasse, H. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.33917 · Cited by 209
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Chen, N., Qian, J., Chen, J., Yu, X., Mei, C., Hao, C., Jiang, G., Lin, H., Zhang, X., Zuo, L., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx011 · Cited by 208
Self-citation
Cardiorenal syndrome: pathophysiology and potential targets for clinical management
Hatamizadeh, P., Fonarow, G. C., Budoff, M. J., Darabian, S., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.279 · Cited by 205
Heart failure in patients with kidney disease
Tuegel, C., & Bansal, N. (2017) · Heart · doi:10.1136/heartjnl-2016-310794 · Cited by 205
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
Haase, V. H. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.002 · Cited by 200
Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M., & Jaber, B. L. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.014 · Cited by 204
Mechanisms of Disease: the hypoxic tubular hypothesis of diabetic nephropathy
Singh, D. K., Winocour, P. H., & Farrington, K. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0757 · Cited by 202
Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
Holdstock, L., Meadowcroft, A. M., Maier, R., Johnson, B. M., Jones, D., Rastogi, A., Zeig, S., Lepore, J. J., & Cobitz, A. R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111139 · Cited by 200
Traditional and emerging cardiovascular risk factors in end-stage renal disease
Zoccali, C., Mallamaci, F., & Tripepi, G. L. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s85.25.x · Cited by 200
A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)
Benz, R. L., Pressman, M. R., Hovick, E. T., & Peterson, D. D. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70015-6 · Cited by 199
A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study
Lipšic, E., van der Meer, P., Voors, A. A., Westenbrink, B. D., van den Heuvel, A. F. M., de Boer, H. C., van Zonneveld, A. J., Schoemaker, R. G., van Gilst, W. H., Zijlstra, F., et al. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-7680-5 · Cited by 198
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
Ballinger, A. E., Palmer, S. C., Nistor, I., Craig, J. C., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006254.pub2 · Cited by 194
Effect of Variability in Anemia Management on Hemoglobin Outcomes in ESRD
Lacson, E., Ofsthun, N. J., & Lazarus, J. M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50030 · Cited by 194
Restoring invisible and abandoned trials: a call for people to publish the findings
Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013) · BMJ · doi:10.1136/bmj.f2865 · Cited by 192
Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
Kalantar‐Zadeh, K., Lee, G. H., Miller, J. E., Streja, E., Jing, J., Robertson, J. A., & Kovesdy, C. P. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.040 · Cited by 192
The Influence of Inflammation on Anemia in CKD Patients
Gluba-Brzózka, A., Franczyk, B., Olszewski, R., & Rysz, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030725 · Cited by 192
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 188
Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease
Kendrick, J., & Chonchol, M. B. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0954 · Cited by 187
Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure
Bahlmann, F. H., Song, R., Boehm, S. M., Mengel, M., von Wasielewski, R., Lindschau, C., Kirsch, T., de Groot, K., Laudeley, R., Niemczyk, E., et al. (2004) · Circulation · doi:10.1161/01.cir.0000139335.04152.f3 · Cited by 186
Critical and Honest Conversations
Williams, A. W., Dwyer, A. C., Eddy, A. A., Fink, J. C., Jaber, B. L., Linas, S. L., Michael, B., O’Hare, A. M., Schaefer, H. M., Shaffer, R. N., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04970512 · Cited by 184
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure
van der Putten, K., Braam, B. G., Jie, K. E., & Gaillard, S. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0655 · Cited by 182
Reticulocyte Cellular Indices: A New Approach in the Diagnosis of Anemias and Monitoring of Erythropoietic Function
Brugnara, C. (2000) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360091174196 · Cited by 181
Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients
Kuragano, T., Matsumura, O., Matsuda, A., Hara, T., Kiyomoto, H., Murata, T., Kitamura, K., Fujimoto, S., Hase, H., Joki, N., et al. (2014) · Kidney International · doi:10.1038/ki.2014.114 · Cited by 179
Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
Locatelli, F., Nissenson, A. R., Barrett, B. J., Walker, R. G., Wheeler, D. C., Eckardt, K., Lameire, N. H., & Eknoyan, G. (2008) · Kidney International · doi:10.1038/ki.2008.299 · Cited by 176
Self-citation
Protective Effects of Erythropoietin in Cardiac Ischemia
Lipšic, E., Schoemaker, R. G., van der Meer, P., Voors, A. A., van Veldhuisen, D. J., & van Gilst, W. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.031 · Cited by 170
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure
Foley, R. N. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.160271.x · Cited by 173
Cardiovascular disease in chronic renal insufficiency
Levin, A., & Foley, R. N. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19928 · Cited by 168
The Importance of Anemia and its Correction in the Management of Severe Congestive Heart Failures
Silverberg, D. S., Wexler, D., & Iaina, A. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00115-0 · Cited by 167
Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients
Finkelstein, F. O., Story, K. O., Firanek, C. A., Mendelssohn, D. C., Barré, P. E., Takano, T., Soroka, S., & MUJAIS, S. K. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00630208 · Cited by 165
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 164
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 165
Arteriovenous Access Failure, Stenosis, and Thrombosis
MacRae, J. M., Dipchand, C. S., Oliver, M. J., MOIST, L. M., Lok, C. E., Clark, E. G., Hiremath, S. S., Kappel, J. E., Kiaii, M., Luscombe, R., et al. (2016) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358116669126 · Cited by 163
Thrombosis in End‐Stage Renal Disease
Casserly, L. F., & Dember, L. M. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16048.x · Cited by 163
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 162
Self-citation
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
Fishbane, S., Pollock, C. A., El-Shahawy, M., Escudero, E. T., Rastogi, A., Van, B. P., Frison, L., Houser, M., Pola, M., Little, D. J., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020111638 · Cited by 161
Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study
Robinson, B. M., Lin, T., Zhang, J., Wolfe, R. A., Goodkin, D. A., Greenwood, R. N., Kerr, P. G., Morgenstern, H., Li, Y., Pisoni, R. L., et al. (2012) · Kidney International · doi:10.1038/ki.2012.136 · Cited by 158
Self-citation
The erythropoietin receptor in normal and cancer tissues
JELKMANN, W. E. B., Bohlius, J., Hallek, M. J., & Sytkowski, A. J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.006 · Cited by 158
Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999
Khan, S. S., & Pereira, B. J. G. (2000) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2000.00036.x · Cited by 158
Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia
Leaf, D. E., & Goldfarb, D. S. (2008) · Kidney International · doi:10.1038/ki.2008.414 · Cited by 155
Mechanism of erythropoietin-induced hypertension
Vaziri, N. D. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70413-0 · Cited by 154
Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?
Zarychanski, R., & Houston, D. S. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071131 · Cited by 154
Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M. J., Weingart, O., Kluge, S., et al. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007303.pub2 · Cited by 153
Early Outcomes among Those Initiating Chronic Dialysis in the United States
Chan, K. E., Maddux, F. W., TOLKOFF-RUBIN, N. E., Karumanchi, S. A., Thadhani, R., & Hakim, R. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03680411 · Cited by 151
Erythropoietin in cardiovascular diseases
van der Meer, P. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.11.017 · Cited by 151
Anaemia in inflammatory rheumatic diseases
Weiss, G., & Schett, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.183 · Cited by 146
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
Macdougall, I. C., & Eckardt, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69120-4 · Cited by 146
Cardiovascular risk in uraemic patients—is it fully explained by classical risk factors?
Zoccali, C. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.4.454 · Cited by 146
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
Palmer, S. C., Saglimbene, V. M., Mavridis, D., Salanti, G., Craig, J. C., Tonelli, M. A., Wiebe, N., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010590.pub2 · Cited by 144
Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care
Warner, M. A., Shore-Lesserson, L. J., Shander, A., Patel, S. Y., Perelman, S. I., & Guinn, N. R. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004727 · Cited by 144
Vitamin D deficiency and anemia in early chronic kidney disease
Patel, N. M., Gutiérrez, O. M., Andress, D. L., Coyne, D. W., Levin, A., & Wolf, M. S. (2010) · Kidney International · doi:10.1038/ki.2009.551 · Cited by 143
Anaemia management and mortality risk in chronic kidney disease
Hörl, W. H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.21 · Cited by 143
Iron and anemia in human biology: a review of mechanisms
Handelman, G. J., & Levin, N. W. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9086-x · Cited by 143
Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome
Palazzuoli, A., Silverberg, D. S., Iovine, F., Calabrò, A., Campagna, M. S., Gallotta, M., & Nuti, R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.022 · Cited by 143
Pure Red-Cell Aplasia and Recombinant Erythropoietin
Gershon, S. K., Luksenburg, H., Coté, T. R., & Braun, M. M. (2002) · New England Journal of Medicine · doi:10.1056/nejm200205163462015 · Cited by 143
Iron supplementation to treat anemia in patients with chronic kidney disease
Besarab, A., & Coyne, D. W. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.139 · Cited by 142
Self-citation
Safety in iron management
Fishbane, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00373-1 · Cited by 142
Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis
Streja, E., Kovesdy, C. P., Greenland, S., Kopple, J. D., McAllister, C. J., Nissenson, A. R., & Kalantar‐Zadeh, K. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.029 · Cited by 140
Self-citation
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
Provenzano, R., Shutov, E. V., Еремеева, Л. Ф., Korneyeva, S., Poole, L., Saha, G. C., Bradley, C., Eyassu, M., Besarab, A., Leong, R., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab051 · Cited by 140
Self-citation
Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin
Wun, T., Law, L. Y., Harvey, D. J., Sieracki, B., Scudder, S., & Ryu, J. K. (2003) · Cancer · doi:10.1002/cncr.11700 · Cited by 139
Anaemia is an independent predictor of poor outcome in patients with chronic heart failure
Szachniewicz, J., Petruk-Kowalczyk, J., Majda, J., Kaczmarek, A., Reczuch, K., Kalra, P. R., Piepoli, M. F., Anker, S. D., Banasiak, W., & Ponikowski, P. (2003) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00574-0 · Cited by 138
Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end‐stage renal failure
McMahon, L. P., Mason, K. F., Skinner, S. L., Burge, C. M., Grigg, L. E., & Becker, G. J. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.9.1425 · Cited by 138
Anemia in renal disease: Diagnosis and management
Lankhorst, C. E., & Wish, J. B. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.09.001 · Cited by 136
Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment
Locatelli, F., Bommer, J., London, G. M., Martín‐Malo, A., Wanner, C., Yaqoob, M., & Zoccali, C. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.3.459 · Cited by 136
Associates of Mortality and Hospitalization in Hemodialysis: Potentially Actionable Laboratory Variables and Vascular Access
Lacson, E., Wang, W., Hakim, R. M., Teng, M. F., & Lazarus, J. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.031 · Cited by 134
An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection
Bogoyevitch, M. A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.03.017 · Cited by 134
Parenteral iron use in the management of anemia in end-stage renal disease patients
Bailie, G. R., Johnson, C. A., & Mason, N. A. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70294-0 · Cited by 132
Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?
Kazory, A., & Ross, E. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.046 · Cited by 131
Anemia in diabetes: marker or mediator of microvascular disease?
Thomas, M. C. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0378 · Cited by 131
Effect of Early Correction of Anemia on the Progression of CKD
Rossert, J., Levin, A., Roger, S. D., Hörl, W. H., Fouqueray, B. L., Gassmann-Mayer, C., Frei, D. W., & McClellan, W. M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.02.170 · Cited by 131
Left Ventricular Geometry Predicts Cardiovascular Outcomes Associated with Anemia Correction in CKD
Eckardt, K., Scherhag, A. W., Macdougall, I. C., Tsakiris, D., Clyne, N., Locatelli, F., Zaug, M. F., Burger, H. U., & Drüeke, T. B. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060631 · Cited by 131
Hemorheology and Microvascular Disorders
Cho, Y. I., & Cho, D. J. (2011) · Korean Circulation Journal · doi:10.4070/kcj.2011.41.6.287 · Cited by 130
Hemoglobin variability in epoetin-treated hemodialysis patients
Berns, J. S., Elzein, H., Lynn, R. I., Fishbane, S., Meisels, I. S., & DeOreo, P. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00229.x · Cited by 130
Erythropoietic stress and anemia in diabetes mellitus
Singh, D. K., Winocour, P. H., & Farrington, K. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.17 · Cited by 130
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
Martin, E. R., Smith, M. T., Maroni, B. J., Zuraw, Q., & deGoma, E. M. (2017) · American Journal of Nephrology · doi:10.1159/000464476 · Cited by 129
Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge
Levin, A. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.7.x · Cited by 129
Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists
Silverberg, D. S., Wexler, D., Iaina, A., Steinbruch, S., Wollman, Y., & Schwartz, D. (2006) · International Urology and Nephrology · doi:10.1007/s11255-006-0064-8 · Cited by 129
Pharmacological targeting of the HIF hydroxylases – A new field in medicine development
Chan, M. C., Holt‐Martyn, J. P., Schofield, C. J., & Ratcliffe, P. J. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.001 · Cited by 128
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities
Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601377103 · Cited by 127
Epidemiology of cardiovascular risk in patients with chronic kidney disease
Locatelli, F. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg1072 · Cited by 127
The renal patient with coronary artery disease
Gupta, R., Birnbaum, Y., & Uretsky, B. F. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.058 · Cited by 126
Dialyzer membrane permeability and survival in hemodialysis patients
Chauveau, P., Nguyen, H. C., Combe, C., Chêne, G., Azar, R., Cano, N., Canaud, B., Fouque, D. P., Laville, M., Leverve, X. M., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.014 · Cited by 126
Aspirin Prescription and Outcomes in Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
Ethier, J. H., Bragg‐Gresham, J. L., Piera, L., Akizawa, T., Asano, Y., Mason, N. A., Gillespie, B. W., & Young, E. W. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.007 · Cited by 124
Effect of anemia on 1-year mortality in patients with acute myocardial infarction
Falluji, N., Lawrence-Nelson, J., Kostis, J. B., Lacy, C. R., Ranjan, R., & Wilson, A. C. (2002) · American Heart Journal · doi:10.1016/s0002-8703(02)00134-5 · Cited by 124
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD
Umanath, K., Jalal, D. I., Greco, B., Umeukeje, E. M., Reisin, E., Manley, J., Zeig, S., Negoi, D., Hiremath, A. N., Blumenthal, S. S., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080842 · Cited by 120
Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy
Himmelfarb, J. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00659.x · Cited by 120
Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time
Robinson, B. M., Joffe, M. M., Berns, J. S., Pisoni, R. L., Port, F. K., & Feldman, H. I. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00693.x · Cited by 120
IL-1β Receptor Antagonist Reduces Inflammation in Hemodialysis Patients
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C., & Ikizler, T. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070760 · Cited by 120
Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF): A Phase III, Anaemia Correction, Morbidity–Mortality Trial
McMurray, J. J. V., Anand, I. S., Díaz, R., Maggioni, A. P., O’Connor, C. M., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y. P., Swedberg, K. B., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp098 · Cited by 119
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs
Alani, H. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.156 · Cited by 119
Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
Mix, T.-C. H., Brenner, R. M., Cooper, M. E., de Zeeuw, D., Ivanovich, P. T., Levey, A. S., McGill, J. B., McMurray, J. J. V., Parfrey, P. S., Parving, H., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.047 · Cited by 119
Cardiovascular disease in patients with chronic kidney disease
Hutchison, A. J. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6206 · Cited by 118
Cardiovascular disease in chronic renal failure: the challenge continues
Locatelli, F., Marcelli, D., Conte, F., DʼAmico, M., Vecchio, L. D., Limido, A., Malberti, F., & Spotti, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.suppl_5.69 · Cited by 117
Early mortality in patients starting dialysis appears to go unregistered
Foley, R. N., Chen, S., Solid, C. A., Gilbertson, D. T., & Collins, A. J. (2014) · Kidney International · doi:10.1038/ki.2014.15 · Cited by 116

Authors: Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
Affiliations: Henry Ford Hospital (US)
University of Virginia Health System (US)
Amgen (United States) (US)
University of California, Los Angeles (US)
Duke University (US)
ORCID: Bolton, W. Kline
Goodkin, David A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-08-27
Volume: 339
Issue: 9
Pages: 584-590
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199808273390903
OpenAlex: W2331665138
Cited by: 1,930
References: 28
Citations by year: 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
FWCI: 21.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords: hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks